The Business Times
business-time-50

Eli Lilly

Companies & Markets

Competition watchdog seeks public feedback on Zuellig Pharma-Eli Lilly deal

2026-04-02T11:23:31.000Z
The deals include agreements with Eli Lilly and Novo Nordisk to slash the prices of popular GLP-1 weight-loss drugs.
International

Trump unveils TrumpRx discounted drugs website

2026-02-06T02:02:20.000Z
Novo Nordisk has gone from being Europe’s most valuable listed company to losing more than US$300 billion in market value.
Opinion & Features
THINKING ALOUD

How I knew when to start backing Novo Nordisk’s biggest rival instead

2025-10-29T23:00:00.000Z
The company currently operates a commercial site at Gurugram near India’s capital, New Delhi, and has specialised operations at Bengaluru and Hyderabad.
Consumer & Healthcare

Eli Lilly to invest US$1 billion in India contract manufacturing

2025-10-07T01:42:43.000Z
White House Press Secretary Karoline Leavitt holds US President Donald Trump's letter to Eli Lilly CEO David Ricks during a press briefing at the White House in Washington, D.C., July 31, 2025.
International

Trump pressures 17 pharma CEOs to cut US drug prices

2025-08-01T00:44:48.000Z
Zepbound, used to treat obesity, and Mounjaro, a diabetes drug, are in extremely high demand, with Lilly seeking to establish reliable supplies.
Consumer & Healthcare

Lilly to boost obesity drug supply with US$3 billion expansion

2024-12-06T00:12:04.000Z
Lilly’s shot has already been approved in mainland China for weight loss and diabetes, but it remains unclear when it plans to launch the product in the country.
Consumer & Healthcare

Eli Lilly gets nod to launch blockbuster weight-loss drug in Hong Kong

2024-10-28T03:32:18.000Z
Since 2020, Lilly has invested more than US$23 billion into new and existing plants.
Consumer & Healthcare

Eli Lilly shells out US$4.5 billion for new drug development plant

2024-10-02T12:14:27.000Z
Patients who were on weekly injections showed a 94 per cent reduction in the risk of progression to type 2 diabetes, compared with placebo.
Consumer & Healthcare

Lilly's weight-loss drug cuts diabetes risk in overweight patients

2024-08-20T15:47:00.000Z
Lilly will pay US$57 a share in cash for Morphic, or 79 per cent more than the closing price on Friday (Jul 5).
International

Lilly agrees to buy US drugmaker Morphic in US$3.2 billion deal

2024-07-08T14:10:28.000Z
Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
View More